Polarean Imaging plc Announces Positive Results From Pivotal Phase III Clinical Trials
Polarean Imaging plc (AIM: POLX), a clinical stage medical imaging technology company developing a proprietary magnetic resonance imaging (MRI) drug-device combination, today announced positive top-line results from two pivotal Phase III clinical trials of the…
Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting
Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, today announced updated interim clinical data from the ongoing Phase 1 trial of its…
PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the first patient has been dosed in a Phase 2b clinical trial…
PhaseBio Announces Completion of Phase 2a Clinical Trial of PB2452
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary orphan diseases, today announced the completion of its Phase 2a clinical trial of PB2452. Full data…
Polarean Enrols First Patient At University Of Cincinnati Trial Site
Polarean Imaging PLC on Monday announced enrolment of the first patients in its third trial site at the University of Cincinnati in the US and is on track for its third quarter enrolment target. Shares…
PhaseBio: Positive Results from Phase 2a Clinical Trial of PB2452
PhaseBio Announces Positive Preliminary Results from Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor in Older and Elderly Subjects June 17, 2019 16:01 ET | Source: PhaseBio…
Precision Announces Dosing of First Patient
Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS® genome editing platform, announced today it has dosed the first patient in the Phase 1/2a clinical trial of PBCAR0191,…
PhaseBio Reports Full Results from Phase 1 Clinical Trial
PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS) announced today that results from their Phase 1 clinical trial of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, demonstrated that PB2452 provided immediate and sustained reversal of ticagrelor antiplatelet…
PhaseBio Reports Full Results from Phase 1 Clinical Trial
PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS) announced today that results from their Phase 1 clinical trial of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, demonstrated that PB2452 provided immediate and sustained reversal of ticagrelor antiplatelet…